This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
COVID-19, it’s not over! CLL Society will keep hammering away at this topic because we are continuing to hear that the general public, CLL patients, and even healthcare providers are still unaware that COVID-19 vaccines may not reliably protect the immunocompromised. The CLL community is lucky to have fellow patients whose voices of concern have been tremendously amplified by media outlets and have garnered some recent attention. Read about those who have been sounding the alarm on our behalf in the article, “It’s Not Over Yet”: Uncertain Protection from Covid Vaccines Leaves Chronic Lymphocytic Leukemia (CLL) Patients Still At Risk.”Dr. Koffman shares what Michele Nadeem-Baker (CLL patient and cancer advocate), Greg Simon (CLL patient, health policy consultant, and leader of the Biden Cancer Initiative), Dr. Robert Montgomery (transplant surgeon), and Dr. Lindsay Ryan (ER physician who is also immune-compromised) have been saying in the media about this very important subject. It’s no time for silence!
Help When You Need It
Consider sharing these guidelines created by CLL Society with friends and family, which explain why it is still important for those with CLL to continue strict infection control measures for prevention of COVID-19: Explaining to Family and Friends Why the CDC Guidelines for Those Vaccinated Against COVID-19 Do Not Apply to Chronic Lymphocytic Leukemia Patients.
ASH 2020: Dr. Davids Discusses Duvelisib and Venetoclax, an Oral Time-Limited Treatment for Chronic Lymphocytic Leukemia (CLL). The team at Dana-Farber Cancer Institute is testing whether the combination of duvelisib (Copiktra™) and venetoclax (Venclexta®) will lead to deep remissions that would allow for oral only therapy of one year duration. Learn more about this ongoing Phase I/II clinical trial.
There are programs to help with financial assistance for CLL patients and families. These include
the Urgent Needs Program and Co-Pay Assistance Program. These LLS programs can help
CLL patients cover out-of-pocket expenses for labs, scans, tests, insurance premiums, and co-pays,
whether you are in watch and wait or active treatment. The PAN Foundation’s FundFinder is a free
resource to help track whether a patient assistance program and other support services are available. Learn more about these programs and other forms of financial assistance here.
In Case You Missed It
If you missed the June 29th Webinar presented by Lab Scientist Dr. Susan Leclair called, “Learning to Decode Your Blood Test Results” please consider watching at your leisure. It was CLL Society’s highest attended webinar to date! There was so much helpful information shared about how to interpret blood test results and why it is critical to keep track of trending labs in CLL.
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.